Any content you receive is for information purposes only. Always conduct your own research.
*Sponsored
Krypton Street Has BioStem Technologies Inc. (BSEM) At The Top Of Our Screen This Morning —Friday, July 31, 2026
Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Take A Look At BSEM While It’s Still Early… July 31, 2026 Dear Reader, Last look before the open. BioStem Technologies Inc. (BSEM) is at the top of our screen this morning. A Nasdaq uplisting process is underway. A commercial transformation is taking shape. New patents have been issued. Clinical milestones are approaching. And four dated events sit directly ahead, beginning with second quarter results coming soon. The bell rings in about ten minutes. Everything you need is below. 
August 12: second quarter results. August 13: a payment of up to $10M that unlocks a newly cleared device. August 2026: estimated primary completion on a randomized clinical trial. Fourth quarter: the target launch window for that device. Everything below explains why those four dates sit where they do. First, Who This Is
BioStem Technologies Inc. makes placenta and umbilical cord-derived tissue allografts. In plain terms, biological coverings that surgeons and wound care clinicians place on wounds that will not close on their own. Three proprietary processes sit underneath: BioRetain dehydrates, CryoTek cryopreserves, and SteriTek produces a hydrated shelf-stable version finished with terminal gamma sterilization. Dry, frozen, shelf-stable, one portfolio. That range is the pitch, because different sites of care want different formats. Everything runs out of a 6,100 square foot FDA-registered facility in Pompano Beach, Florida, accredited by the Association for Advancing Tissue and Biologics, with multiple ISO 5 and ISO 7 clean suites. The company was founded in 2006 and operates with roughly 73 employees. Brands include Neox, Clarix, VENDAJE, American Amnion, AmnioWrap 2 and VENDAJE OPTIC. Behind them, 68 issued patents and 81 pending applications, plus four design patents granted July 8. The target patients are the ones whose wounds do not close: diabetic foot ulcers, venous leg ulcers, pressure ulcers, traumatic wounds, post-surgical incisions. Management's stated strategy runs on four pillars. Widen the sites of care into hospital inpatient, outpatient and ambulatory surgical settings. Broaden the portfolio across wound care and surgical uses. Scale the commercial organization and payer coverage. And pull manufacturing in house to expand margin. Why August 13 Matters
In June, BioTissue received 510(k) clearance for Catalyze, an advanced wound care device. Under the January acquisition, once conditions are satisfied and up to $10.0M is paid, the U.S. commercial rights transfer to BSEM. The company currently expects that payment on August 13, with a launch targeted for the fourth quarter. One day after earnings. Why August 12 Matters It is the first full quarter reported with the rebuilt commercial organization at full strength. Rewind to first quarter results on May 14. Net revenue $6.1M, gross margin 61%, and hospital channels at roughly 87% of the total. The direct sales force had gone from 18 representatives to 35. All GPO contracts reassigned. Cash at $13.7M. Full-year guidance of $25M to $29M. That 87% is the number to hold onto. A year ago this was a physician-office company. The January purchase of BioTissue's surgical and wound care business brought over the Neox and Clarix brand rights, two orthopedic patents, licenses to the CryoTek and SteriTek patents, BioTissue's direct reps, its independent agent agreements, and its GPO and Integrated Delivery Network contracts. The rest of the quarter looked like an integration quarter, because it was one. Operating expenses of $12.6M. A GAAP net loss of $8.8M, or $0.52 per share. Adjusted EBITDA of negative $5.7M. Intangibles climbing from about $0.1M at year-end to $21.9M. The margin story has a second act. The acquired Neox and Clarix products currently carry a cost-plus markup under the BioTissue supply agreement, which is what pulled gross margin to 61% from 97% in the prior quarter. Management expects that to improve once the manufacturing technology transfer completes and production moves into the Pompano Beach facility. Q2 tells you whether the machine is actually running. Why the Nasdaq Clock Is Ticking
On July 10, BSEM publicly filed a Form 10 registration statement with the SEC and reaffirmed its decision to pursue a Nasdaq listing. The registration goes effective once the SEC finishes its review, and that step has to clear before any uplisting. A month earlier, the board was rebuilt for the occasion. Mark Glickman, Steven D. Sonenreich and Rayna Lesser Hannaway joined as independent directors effective June 5, placed across Audit, Corporate Governance and Nominating, and Compensation. Who Else Is Watching H.C. Wainwright analyst Swayampakula Ramakanth initiated coverage on BSEM and holds a Bullish view with a $7 target, according to TipRanks. The company has also been working the small-cap circuit, presenting at the 16th Annual LD Micro Invitational on May 12 and the Planet MicroCap Las Vegas 2026 Conference on June 17. The Market Underneath the Dates
Zoom out and the category is doing fine regardless of what any single company does. Precedence Research puts the global advanced wound care market at $16.33Bn in 2025, climbing from $18.90Bn in 2026 to approximately $67.31Bn by 2035, a compound annual growth rate of 15.22%. Run the math on those two endpoints and it is better than 250% growth inside a decade. A category that nearly quadruples in nine years does not need any single company to cooperate. It just needs the wounds to keep coming, and they will. North America held 47% of 2024 revenue, with the U.S. portion alone sized at $5.37Bn in 2025. Now narrow it to the part BSEM actually plays in. Hospitals were 48% of 2024 revenue, roughly $4.1Bn, the largest end-user segment in the category. BSEM booked approximately 87% of its first quarter revenue from hospital channels. Within the product taxonomy, skin substitutes fall under active wound care, which is where placental allografts belong. Within applications, chronic wounds break out into pressure ulcers, diabetic foot ulcers, venous leg ulcers and arterial ulcers. BSEM sells across those categories and has run randomized trials in two of them. Pressure ulcers deserve their own line. More than 2.5M Americans develop them annually, at a U.S. treatment cost of $9.1Bn to $11.6Bn. That is the indication CMS left outside the new Local Coverage Determinations, and the one BSEM says accounts for the majority of its Medicare-related revenue. The Reimbursement Picture, Both Sides CMS replaced ASP plus 6% with a flat $127.14 per square centimeter effective January 1. BSEM reports the change cut physician-office revenue per square centimeter by up to 95% in some cases. The offset: in December, CMS put VENDAJE and VENDAJE AC on a 12-month status quo list and confirmed the new Local Coverage Determinations cover diabetic foot ulcer and venous leg ulcer indications only. Pressure ulcers, which the company calls the largest segment of the chronic wound market and the primary source of its Medicare-related revenue, sit outside the change. The Evidence Behind It
Last October, BSEM published randomized controlled trial results in the International Journal of Tissue Repair. Using complete wound closure as the endpoint, the healing probability was 53% with BioRetain Amnion Chorion against 31% for standard of care. The design is stricter than most in this field. BR-AC-DFU-101 ran across 11 U.S. sites and enrolled 71 patients with Wagner grade 1 or 2 ulcers. Everyone went through a two-week run-in on standard care first, and any wound that shrank more than 30% during that period was excluded from randomization. The easy healers never made it into the study. Bert Slade, chairman of the company's medical advisory board, called that level of rigor unusual for the published literature here. The venous leg ulcer trial is the one hitting estimated primary completion this month. It is a multicenter randomized study targeting at least 60 subjects with non-healing, non-infected ulcers and confirmed venous reflux, with complete closure over 12 weeks as the primary endpoint. No top-line data reported yet. A third study, in diabetic foot ulcers using the BioRetain amniotic membrane product, is also running. For Friday July 31, 2026: 7 Reasons Why BSEM IsOn Our Screen
This Morning When The Bell Rings… 1. Upcoming Dates: BSEM enters August with second quarter results, an expected commercial rights milestone, a randomized trial milestone, and a targeted fourth-quarter device launch all scheduled within a short timeframe. 2. Nasdaq Path: BSEM has publicly filed its Form 10 registration statement with the SEC, a required step before a potential Nasdaq uplisting can move forward. 3. Hospital Shift: Approximately 87% of BSEM's first-quarter revenue came from hospital channels following its BioTissue acquisition and commercial expansion. 4. Clinical Evidence: BSEM published randomized controlled trial results showing a 53% probability of complete wound closure versus 31% for standard of care. 5. Patent Portfolio: BSEM's technology platform is supported by 68 issued patents, 81 pending applications, and four additional U.S. design patents granted in July. 6. Analyst Coverage: BSEM is followed by H.C. Wainwright, where analyst Swayampakula Ramakanth maintains a Bullish rating with a $7 price target, according to TipRanks. 7. Growing Market: The advanced wound care sector where BSEM operates is projected by Precedence Research to grow more than 250%, from $18.90Bn in 2026 to $67.31Bn by 2035. Take A Look At BSEM While It’s Still Early…
Four dated events inside sixty days, a listing application in SEC review, published clinical data, and a prospectus that lays out the risks in the company's own words. Mark the calendar, read the filing, and decide for yourself. We’re watching BSEM this morning as the bell is about to ring. My next update could be on its way soon, keep an eye out for it. Sincerely, Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter |
Inside: Your best night's sleep starts with these must haves
Having trouble using Hometalk? 
